Highlights from the VIII ICAPEM Symposium by Jarushka Naidoo

The VIII ICAPEM Symposium, held on November 7, 2024, was a landmark event in the field of clinical medicine and medical research.

The International Conference on Advanced Practices in Experimental Medicine (ICAPEM) has long been an established platform for promoting scientific knowledge and best practices in medicine. The VIII ICAPEM Symposium was an integral part of this ongoing effort, offering a unique opportunity for professionals from around the world to come together and exchange ideas at the forefront of medical advancement.

Coordination and Expertise

The symposium was expertly coordinated by three renowned professionals from prominent Spanish hospitals:

Dr. Dolores Isla (Lozano Blesa University Clinical Hospital, Zaragoza): A leading expert in oncology, Dr. Isla has made significant contributions to the treatment and management of cancer patients, focusing on improving survival rates and quality of life.

Dr. Javier de Castro (La Paz University Hospital, Madrid): Known for his research in clinical trials and advanced treatment protocols, Dr. de Castro’s work has been particularly influential in the fields of immunotherapy and personalized medicine.

Dr. Laura Mezquita (Hospital Clínic, Barcelona): Specializing in integrating novel therapies into clinical practice, Dr. Mezquita’s research addresses complex medical conditions, with an emphasis on precision medicine and translational research.

Dr. Rosario Perona: The Deputy Director General of Research in Cell Therapy and Regenerative Medicine at the Carlos III Institute in Madrid, Spain. She is a leading expert in cell therapy and regenerative medicine, focusing on advancing innovative treatments for degenerative diseases and other conditions.

About ICAPEM

The Association for Research on Lung Cancer in Women (ICAPEM) is a non-profit organization founded on December 29, 2010, by a group of specialists dedicated to the diagnosis and treatment of lung cancer. ICAPEM’s mission is to raise awareness about the impact of lung cancer in women, provide support to patients, and contribute to scientific progress through research and education.

The organization focuses on improving patient outcomes, advancing research into lung cancer in women, and offering training for healthcare professionals to stay updated on the latest clinical practices and treatments. Through its initiatives, ICAPEM aims to make a significant difference in the lives of women affected by lung cancer.

Jarushka Naidoo, Thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University, shared her insights from VIII ICAPEM Symposium:

Super session by Lorenza Landi, Pilar Garrido et al:

“Super to be in Madrid at VIII Simposio ICAPEM talking about the role of gender in lung cancer. Kicking off with a super session by Lorenza Landi, Pilar Garrido et al on prevention and survivorship”

Super session at VIII Simposio ICAPEM on lung cancer clinical trials:

“Super session at VIII Simposio ICAPEM on lung cancer clinical trials, fascinating that:

– more women take part to trials when lead authors are women!
– Women take part in less lung cancer clinical trials v men
– ENGAGE study will aim to understand why”

Sex and Gender Perspective on Lung Cancer:

“Thanks VIII Simposio ICAPEM for the opportunity to present a Sex+Gender Perspective on Lung Cancer

Key messages:

– Incidence of LC in young Women is High
– Less women take part in LC trials
– gender diffs in IO outcomes exist Congrats.

ICAPEM for raising the bar through research.”

The best thing about meeting:

“VIII Simposio ICAPEM

The best thing about meetings- building community, seeing friends, learning, and planning new collaborations Congrats on an enriching program!”

More posts featuring Jarushka Naidoo on oncodaily.com

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.

She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.